Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in St Germain En Laye – page 58

3 345 clinical trials in St Germain En Laye, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
St Germain En Laye at a glance
3 345
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 345 trials in St Germain En Laye

Open in trial search

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study on Carvedilol for Preventing Complications in Patients with Early-Stage Cirrhosis and High Blood Pressure in the Liver

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carvedilol
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

Study on EXL01 for Preventing Crohn's Disease Recurrence After Surgery in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EXL01
  • Sponsor:Groupe De Recherche Sur Les Maladies Inflammatoires Digestives

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

HIV infection

Recruiting

Study Comparing Doravirine/Lamivudine and Dolutegravir/Lamivudine for HIV Patients with Controlled Viral Load on Three-Drug Regimens

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Eidos Therapeutics Inc.

Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study Comparing Sodium Chloride and Sodium Lactate for Treating Severe Diabetic Ketoacidosis in ICU Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nice

Study on Cabozantinib and Nivolumab for Older Patients with Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Endometrial cancer+18

Recruiting

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sevabertinib
  • Sponsor:Bayer AG

Study on Human Albumin Solution and Ringer Lactate for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mannitol
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in St Germain En Laye

What the registry says about research in the country

01 Hematologic Oncology

Investigating innovative combination therapies for follicular lymphoma, comparing mosunetuzumab plus lenalidomide against standard treatments to improve progression-free survival in previously untreated patients.

  • Advanced lymphoma treatments
  • Targeted therapy combinations
  • Novel therapeutic approaches

Research focuses on enhancing treatment outcomes for high-risk lymphoma patients.

02 Breast Cancer Research

Evaluating treatment strategies for elderly women with HER2-negative breast cancer, examining the effectiveness of combined chemotherapy and hormone therapy based on genomic profiling.

  • Age-specific treatment protocols
  • Personalized therapy approaches
  • Genomic-guided interventions

Studies aim to optimize treatment outcomes for senior patients while considering their specific needs.

03 Neurological Disorders

Investigating treatment optimization for Secondary Progressive Multiple Sclerosis patients, focusing on the safety and efficacy of disease-modifying therapy withdrawal in stable patients over 50.

  • Treatment discontinuation studies
  • Age-specific MS management
  • Long-term disease monitoring

Research aims to enhance quality of life while maintaining disease stability.

04 Maternal Health

Examining preventive strategies for pregnancy-associated hypertension and pre-eclampsia through controlled trials of acetylsalicylic acid treatment in pregnant women with chronic hypertension.

  • Maternal-fetal outcomes
  • Preventive interventions
  • Pregnancy complications

Focus on reducing maternal and fetal morbidity through preventive care.

05 Endocrine Surgery

Investigating the effects of preoperative cholecalciferol supplementation on post-thyroidectomy outcomes, specifically focusing on preventing hypocalcemia complications.

  • Surgical outcome optimization
  • Preventive supplementation
  • Post-operative care

Research aims to improve patient recovery and reduce hospital stays after thyroid surgery.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.